LCTX vs EVGO Comparison

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

EVgo Inc is an EV fast charging provider. The company deploys charging infrastructure by partnering with retailers, grocery stores, restaurants, gas stations, rideshare operators, and autonomous vehicle companies across the U.S., and serves the EV commercial segment by deploying fleet-charging solutions for light-duty EV fleets at depot locations, off-site charging hubs, or through its public network. It also owns PlugShare, a platform for EV drivers to locate public charging stations, plan trips and share charging experiences, which also provides charging location data licensing, infrastructure analysis, and EV driver research. It also derives revenue from the sale of regulatory credits earned from participation in LCFS programs and other carbon or emissions trading schemes in the U.S.